1. Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center
- Author
-
Joana Maciel, Davide Fraga, Helder Simoes, Sara Donato, Rita Sousa, Joana Simões-Pereira, and Daniela Cavaco
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Endocrinology, Diabetes and Metabolism ,Cohort ,medicine ,Cancer ,Center (algebra and category theory) ,General Medicine ,business ,medicine.disease - Abstract
Purpose: The use of FDG-PET/TC for cancer staging has been leading to the increasing diagnosis of adrenal lesions, which usually represent a clinical challenge. Our aim was to characterize the adrenal lesions found in FDG-PET of patients followed in a cancer center.Methods: Retrospective analysis of all FDG-PET studies performed in our center in the last 10 years. Exams reporting adrenal lesions in the CT component and/or anomalous adrenal FDG uptake were selected. Cases were characterized regarding clinical, laboratorial, imaging and pathological findings. Results: We identified 27,427 FDG-PET studies. Of those, 7.6% evidenced adrenal findings. We included 1364 exams corresponding to 1021 patients. Only 15.6% were referred to the endocrinology department and 38% of the lesions were not studied.Malignant lesions were present in 38.9% of the studied patients: metastases in 37.5%, carcinoma in 1.2% and other malignant tumors in 0.4%. Median SUVmax of malignant lesions was significantly higher than the SUVmax of the benign findings (p0.05). Conclusion: Occult adrenal lesions discovered during FDG-PET/CT are common in cancer context and are frequently benign. SUVmax may be a useful tool in the workup of adrenal lesions but with several important caveats.
- Published
- 2022